Sign in Membership
Pricing & Procurement Governance

China’s C-List and Beyond: Group Insurance, Provider Uptake, and Commercial Payment Strategies

A practical implementation deep-dive with Professor Wanyan on China’s C-List and broader commercial payment landscape — covering group health insurance, provider uptake, cross-stakeholder bottlenecks, orphan therapy coverage, TPAs, and scalable payment strategy.

Access360 Audio Briefing

An expert conversation accompanied by a written synthesis for quick executive review.

In Part III of NRDL+'s latest Access360 interview with Professor Wanyan, whose roles include director of the China Insurance Development Research Center at Southwestern University of Finance and Economics, we explored the early rollout and implementation dynamics surrounding C-List integration with group health insurance, provider adoption, and a major bottleneck that could complicate alignment across insurers, manufacturers, and hospitals.

Building from these implementation questions, we also explored broader commercial payment strategy issues, including what makes a sustainable payment solution for orphan therapies, the evolving role of third-party administrators (or TPAs), which in some respects play a PBM-like role in China’s commercial insurance ecosystem, and the essential capabilities manufacturers need to build a scalable commercial payment strategy for medical technologies.

Not yet a member?

Access360 membership provides structured intelligence on China’s evolving health policy, coverage, and financing system, with member briefings, archive access, and opportunities to submit questions on published analyses.

Explore Membership

You might also like...

Jun 10, 2026

China’s C-List in Practice: Early Huiminbao Integration Signals

A practical discussion with Professor Wanyan on Huiminbao benefit design changes, regional adoption differences, local negotiation dynamics, and what early implementation may signal for broader commercial insurance integration.
Jun 03, 2026

China’s C-List: Behind-the-Scenes Negotiation Dynamics

A practical implementation deep-dive into China’s 2025 C-List negotiation process with Professor Wanyan — covering insurer participation, NHSA’s role, selection criteria, pricing negotiation, and future commercial insurance formulary trends.
May 15, 2026

China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline

China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.
Mar 12, 2026

RWE and the Quiet Rewiring of China’s Reimbursement System

Five recent policy releases show how real-world evidence is quietly reshaping pricing, reimbursement, and clinical adoption for both innovative and established medicines in China.
Feb 12, 2026

Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma

China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.